Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, AXSOME THERAPEUTICS, INC. reported revenue of $638M, up 65.5% year over year. Operating margin was -26.1% and net margin -28.7%, on a free-cash-flow margin of -14.7% with capital expenditure at 0.1% of revenue. Every figure is computed directly from AXSM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $638M | -26.1% | -28.7% |
| FY2024 | $386M | -72.7% | -74.5% |
| FY2023 | $271M | -85.7% | -88.4% |
| FY2022 | $50M | -359.3% | -374.0% |
| FY2021 | n/a | n/a | n/a |
How does AXSM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.